Drug Profile
Litapiprant - Sunshine Lake Pharma
Alternative Names: LitapiprantLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Sunshine Lake Pharma
- Class Antiasthmatics; Carboxylic acids; Indoles; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (PO, Tablet)
- 22 Oct 2018 Phase-I clinical trials in Asthma (In volunteers) in China (PO) (ChiCTR1800018994) (NCT03663686)
- 12 Sep 2018 Sunshine Lake Pharma plans a phase I trial for Asthma (In volunteers) in September 2018 (NCT03663686)